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In this pre-formulation study, the effect of individual factors influencing the penetration rate of 
drugs incorporated in various topical vehicles has been in-vitro investigated. The water poor soluble 
prednisolone is chosen as a model drug. To increase the dissolution behavior of prednisolone (P), co-
precipitates of it with polyvinyl-pyrrolidone25, (P/PVP25-coprs), polyethylene glycol6000, (P/PEG6000-coprs) 
and adsorbents with Aerosil200 (P/A-200-adsrob) were prepared and in-vitro tested. A significantly increased 
dissolution in purified water was obtained with the co-precipitate F1, consisting of 10-wt% prednisolone 
and 90-wt% PEG6000. As F1 was incorporated in various model-vehicles insignificant penetration profile 
was achieved. This effect was in fact due to the high concentration of PEG6000 in the vehicles, which has 
increased the bulk viscosity of the ointments, that resulted on the one hand in restricted drug particles 
movement between the phases and on the other between the external phase and the artificial membrane. In 
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contrast, F2 consisted of 50-wt% Prednisolone and 50-wt.%/ PEG6000-copr, showed a slight increase in drug 
solubility compared to the corresponding physical mixture as well to pure P. As F2 was incorporated in 
aqueous emulsifying wool wax-base, (WHES) a greater penetration rate into the synthetic membranes has 
resulted, and no change in the crystal form of P could be observed throughout the study time period of 70 
hours. All other pre-formulations, (prefs) showed negligible increase in the solubility of P. X-ray 
diffractions studies of prednisolone-PVP25-coprs and those of drug/Aerosil200-adsorbent, indicated changes 
in the crystal form of P into monohydrate, which probably happened during the co-precipitation and 
adsorption of the drug and also during the incorporation of the pre-formulations into ointments. This change 
was specifically due to the very few amount of water present in ethanol 96 %v/v used as solvent for the 
preparation of the P-co-precipitates and adsorbents (= prefs) and also due to water available in the external 
phase of all used o/w-emulsions type ointment-bases. 
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INTRODUCTION                  
Prednisolone (P) has moderate anti-allergic and anti-inflammatory actions. This advantage is 
often used topically to treat various skin diseases1. Prednisolone is poor water-soluble, and it forms 
with water a sparingly water-soluble monohydrate (mhydr). Moreover, micronized prednisolone 
particles tend to agglomerate, resulting in reduction of the available surface area that might 
additionally affect negatively drug solubility in the outer aqueous phase of  o/w-emulsions type topical 
vehicles, and hence lower its optimal release behavior from the vehicle2, 3, 4. Ointments are multi-
phase disperse systems, having dermal actions that comprise a complex process by which not only 
the active substance, but also the vehicle as well as the skin itself could play a significant role5. In 
dermatology it is to differentiate between high and low permeable skin types6. Thus, the choice of a 
vehicle is usually determined by one of these two factors. When o/w-bases are used; water will 
evaporate, leaving behind a cooling and anti inflammatory effect that might make the desired 
corticosteroid therapy more efficient7, 8. Generally, for a substance to penetrate into the skin, a 
specific amount of it must initially dissolve in the vehicle. The dissolution rates of a substance in a 
base determine the extent and rate of penetration into the skin. Moreover, the penetration of a 
dissolved drug into the skin is often dependent on the drug’s partition-, and diffusion-coefficient that 
exist between the external and internal phases9. An increase in the dissolution rate of prednisolone in 
the aqueous phase of a w/o-vehicle may enhance its penetration rate into the horny layer, which might 
probably results in therapy optimization and reduction in treatment-costs. Methods to improve the 
dissolution rate of a drug in the vehicle other than particle size reduction are many. One such a 
method is to dissolve the drug in an organic solvent, suspend in the drug solution hydrophilic non-
toxic drug-carriers, or -adsorbent having a large surface area and a porous particle structure, and 
subsequently evaporate the solvent to complete dryness. On the surfaces of each obtained product, 
the drug may probably lie loose, and when it contacts water, an improved drug dissolution rates may 
results10, 11. To achieve this effect, prednisolone was dissolved in ethanol 96 %v/v, and in the resulting 
drug solution excess amounts of PEG6000, PVP25 and A-200 were suspended respectively and 
subsequently the solvent was withdrawn from the preparations.  
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The purpose of this study was to improve via technological means the in-vitro penetration rate 
of prednisolone into artificial membranes and to investigate factors that might have an influence on 
the penetration of the drug.    
 
2. MATERIAL AND METHODS 
2.1. MATEIALS 
Micronized prednisolone, tetrazole blue, ethanol 96v/v%, methanol, (Merck KGaA, Darmstadt, 
Germany), hydrophilic fumed silica (Aerosil-200®, A-200) (Degussa AG, Dűsseldorf, Germany), polyvinyl-
pyrrolidone25 (Kollidon = PVP25), polyethylene glycol6000, (PEG6000), (BASF AG, Ludwigshafen, 
Germany), dimeticone oil200, dodecanol, collodion 4%v/v, chloroform, potassium hydroxide, 
(Laborchemie, Apolda, Germany). All substances used were of pharmaceutical grade.  
 
2.2. METHODS:  
2.2.1 Preparation of the pre-formulations, (pref.) 
Prednisolone-co-precipitates, (P/copr.) and –adsorbents, (P/adsorb) were prepared by dissolving 
excess weights of prednisolone (P) in ratios of 1:9 and 1:1, (1.0 g and 5.0 g) in 250.ml ±2% ethanol 96 
%v/v. Corresponding weights of PEG6000, PVP25 and Aerosil200, (each 9.0 g and 5.0 g) were suspended in 
the drug solutions and the resulted suspensions were then stored for 4 hours at 25ºC 2º to facilitate P 
dissolution and sufficient swelling of the drug/carriers/adsorbents. The solvent was then withdrawn via a 
vacuum rotary evaporator at 70-80ºC and to ensure complete solvent-removal, all samples were placed over 
silica gel in vacuum desiccators for 72 hours and again in a vacuum oven by 25ºC  2º for 8 hours11.  
2.2.2. Saturation solubility of prednsolone- and –monohydrate in pure water 
Excess weights of predinsolone (250.0 g) and monohydrate; (262.2g) were dissolved in 100.0 ml 
±2% pure water. The solutions were gently shaken for 4 days at 25ºC 2º. The resulted saturated solutions 
were centrifuged by 500rpm and subsequently filtered through a filter medium of 0.5m diameter (G4, 
Sartorius, Germany). 2.0 ml ± 2% of the filtrates were withdrawn, and diluted with purified water to 100.0 
ml ±2%, (n = 6). These concentrations were then detected in a UV spectrophotometer at max = 248 nm 
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(UV 240, PC 286, Shimadzu scientific instruments Inc.). The measured saturation concentrations for 
prednisolone and its monohydrate were 97.1 g/ml 27.4 g/ml respectively.   
 2.2.3. Dissolution test for pure prednisolone & the prednisolone pre-formulations, (P/pref.) 
Excess weights of prednisolone (25,0 mg), and the corresponding amounts of 10-wt% P/prefs; (2.5g 
P-wt10% co-precipitate/adsorbent, and 0.5 g of the 50-wt% P + 50-wt.% carriers) were placed in a paddle 
apparatus DT600 (Erweka, Germany), previously filled with 1.0 L ± 2% purified water, having a constant 
temperature of 37ºC ± 2% and a rotation speed of 50 rpm. The maximum dissolution test time period was 
6 hours (hrs). At predetermined time points aliquots of 5.0 ml ±2% were withdrawn and each removed 
sample was replaced with an equal volume of pure water, and the samples were appropriately filtered via a 
0.5m filter-medium (Sartorius, Germany) and analyzed by UV at  = 248 nm. Six tests were made and 
the results recorded as an average.       
 2.2.4. Saturation solubility of prednisolone in soft liquid paraffin and light fluid wax 
Soft liquid paraffin and light fluid wax were constituents of some used vehicles; therefore it is 
important to determine prednisolone saturation solubility in both fluids. 255.0 mg P was dissolved 
respectively in 100.0 ml ± 2% soft liquid paraffin and light fluid wax200. The samples were then shaken for 
4 days at room temperature to achieve saturation solubility. Afterwards the samples were centrifuged by 
1400rpm for 25 minutes and subsequently passed through a 50m filter medium under vacuum. The 
saturation solubility for both soft liquid paraffin and light fluid wax were 79.0g/ml and 29.5g/ml 
respectively. 
2.2.5. Preparation of the synthetic membranes 
The in-vitro penetration evaluation was preformed on artificial multi-layer membrane system 
described previously12, 13. A defined amount of each pref (10mg) was applied onto the acceptor system that 
was placed in a cell having a fixed application area of (4 cm2). The acceptor-system consists of a mono-
membrane, chosen to maintain sink environment. The experiments were carried out six-fold on a 
temperature controlled water bath at 32ºC±2. At a predetermined time points, the assembly was removed 
from the water bath, each membrane was rubbed from excess ointment, extracted with chloroform. 
2.0ml±2% were withdrawn from each extract, mixed with 0.2ml±2% of a 0.5% tetrazole blue chloride 
solution and subsequently 0.3ml of a 0.03 molar methanolic potassium hydrochloride solution was added. 
The drug concentration was analyzed photometrically by   525nm.    
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2.2.6 Powder X-ray diffractometry 
Wide angle X-ray scattering measurements were done on a Philips type Micron 1011, X-rays 
generator having a copper anode (Ni-filtered Cu K radiation,  = 1.5418.10-1 nm, 40 kV/30mA, Philips 
industrial & Electro acoustic systems divisions, Almelo, Holland). The radiation scattered in the crystalline 
section of the samples was measured with a vertical diffraction control unit (URD 63 (Freiburger 
praezisionsmechanik GmbH, Freiburg, Germany). Patterns were obtained by using a step width of 0.02º 
with a detector resolution in 2 between 4 and 40 at 25C.    
 
3. RESULTS AND DISCUSSION 
3.1 Dissolution behavior of P, its -monohydrate. and the pre-formulations 
The results of the dissolution patterns of pure P, and the P–prefs, F1, (10-wt%P + 90-wt% PEG6000), 
F2, (50-wt% P + PEG6000), A1; (10-wt% P + 90-wt Aerosil
200 = A-200): A2, (50-wt P/A-200); F3, (10-wt% 
P/90-wt% PVP25) and F4; (50-wt% P/PVP25) and their quantitative composition are presented in Figure 1 
and listed in table 1.  
Figure 1, showed that P is poor water-soluble, and after 6 hours, only negligible increase in its 
solubility has occurred. In contrast, the dissolution of the copr F1 was significantly enhanced compared to 
that of pure P. Moreover, the curve profile of F1 indicated that in the first hour higher saturation solubility 
was obtained and it remained approximately constant for 6 hours. This effect was probably due to the high 
amount of PEG6000 (90-wt %) present in the pref. PEG6000 is water-soluble, with a relatively high surface 
area that might have enhanced the wettability of P, which may improve its solubility10, 11. 
The dissolution patterns of the prefs, A1, A2, F3 and F4 indicated insignificant increase in dissolution 
during the entire test time period. However, the copr F2, showed a slight enhancement in dissolution profiles 
compared to that of pure prednisolone.  
To evaluate any changes in the crystal form of P that might have happened during the preparation 
of P/prefs, X-ray diffraction studies for pure P, its mhyd, the coprs, F1, F2 and their corresponding physical 
mixtures were made and the results listed in table-2.  
PVP25 is an amorphous material14, 15. Our X-ray diffraction patterns, (XRDP) of the physical 
mixture, consisted of 10-wt% P and 90-wt% PVP25 showed that the mixture was completely amorphous. 
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Only two insignificant small peaks at 2 = 15.4º and 17.4º were present. The XRDPs of F3 indicated the 
presence of small peaks similar to those of pure PVP25, (no graph, presented). A comparison of the XRDPs 
of F4 with those of the corresponding physical mixture showed that P was partially changed into mhyd, 
happened during the co-precipitation of P with PVP25. Thus, the peaks at 2 =14.25 and 15.55 were of 
the mhyd (2 = 14.3 and 15.6). The shoulders at 2 = 13.8, as well the peaks at  15.0, 16.2 and 
17.9º indicated that unchanged P was also available.  
Aerosil200 is an amorphous material with large surface area 17, 18. The XRDPs of a physical mixture 
consisted of 10-wt% P and 90-wt%-Aerosil200 showed very small peaks at 2 = 15.5º and at 20.23º, but 
because of their shorter heights, their position could not be exactly determined. Presumably the peak at 
15.5º was of P (pure P at 2 = 15.1º) and not of the mhyd (2 = 15.6º).  
The XRDPs of the corresponding adsorbent A1 showed a single peak at 2 = 15.5º, indicating the 
presence of a very few amount of P. This change has probably occurred during the adsorption of P on the 
surface of A-200, whereby some amount of P has changed into amorphous state, happened due to the few 
amount of water present in ethanol 96%v/v16. The XRDPs of A2 (no Figure shown.) showed very short 
peaks at 2 = 13.8, 14.25, 15.1, and at 15.4, 15.8, 16.2, 17.6. A comparison of these peaks with those 
of P and its mhyd showed slight deviation in their positions, suggesting that both crystal forms were present 
in the same mixture. When considering the heights of the peaks as a measure, it is possible to predict 
approximately the amount of P changed into mhyd. A comparison of the XRDPs of F4 with those of A2, 
showed that the adsorption of P on the surface of Aerosil200 has changed the crystal form of a few amount 
of P into its mhyd.  
PEG6000 is a crystalline polymer, water-soluble, has a helical structure, and hence is capable to 
transform drugs into hydrates19, happens by entrapping small drug-molecules in his double helical structure, 
in the sense of a solid solution, that might result in enhanced solubility of drugs. The peaks presented in 
table 2 permits two statements:  
First, no change in the crystal form of P has occurred, amorphous conditions were not present. 
Second, the position of the peaks deviates in some cases from those of pure P. The peaks were often 
rounded, because of the low concentration of P in the mixture, so that their exact positions could not easily 
be determined. Thus, the XRDPs confirm the conclusion that P laid mostly in the P/PEG6000-coprs as a pure 
drug. XRDPs of the physical mixture showed peaks at 2 = 15.5 and 15.8, which could not clearly be 
ordered either as of P or of pure PEG6000. In fact, the presence of mhyd in this mixture was unusual and 
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normally should not be available. Eventually, it is possible that due to the hygroscopic nature of PEG6000, 
the mixture might have adsorbed atmospheric moisture, which transformed the crystal form of P into mhyd.  
As shown previously, F1 indicated a significant increase in dissolution behavior compared to 
untreated drug and to the other prefs. This situation permits the conclusion that the enhanced dissolution 
profile of F1 could not be explained as a result of change in the crystal form of P rather due to the larger 
surface area of PEG6000, its crystalline nature, high water-solubility and its higher surface-adsorption 
capacity, which resulted in enhanced P-wettabilty that has produced a higher dissolution profiles. 
3.2 VEHICLES   
The spectrum of the used ointment-bases comprises o/w- and w/o-emulsions type ointment-bases. 
Table 3 shows the quantitative composition of the vehicles used for the in-vitro penetration into the 
artificial mono-membranes.  
3.3. Evaluation of the results of the in-vitro penetration profiles of P/pre-formulations incorporated 
in various o/w- and w/o-emulsion type model-vehicles. 
The extend of the in-vitro penetration into the synthetic membranes depended on the type of vehicles 
used and on the crystal form available in the base at the observation time period, was very different. WHES-
SR is o/w-emulsion type ointment-base, meaning that only the amount of drug dissolved in the aqueous 
external phase can enter into the lipophilic membrane. A comparison of curve 1 (P) with curve 2 (mhyd) in 
Figure 2 confirms this statement. The amount of mhyd entered into the membranes was the lowest. As 
shown previously, P is more soluble in water (97.1 g/ml) than the mhyd (27.4g); also F1 indicated 
improved aqueous dissolution behavior. As F1 as well as all other 10-wt% P/prefs were incorporated in 
WHES, no increased penetration rates could be obtained. In contrast, as A2, F2 and F4 were incorporated in 
WHES, a significant penetration profiles were achieved, compared to that of pure P. Thus, the different 
penetration rates of P released from the ointments (S-1 and S-2) explain on the one hand the importance of 
the drug solubility parameter in the outer water phase; and on the other hand, it is also important to consider 
that the drug-carriers/adsorbent might have changed negatively the physical parameters of the vehicle (e.g. 
viscosity, partition- and diffusion- co-efficients). PEG6000 and PVP25 are water- and lipoid-soluble; hence 
both carriers could change the properties of both the external and internal phases of w/o-vehicles.  
Aerosil200 is capable to build gels with water and hydrophobic materials, a property that could also 
change the physical parameters of both phases of o/w-emulsions. Accordingly, the amounts of Aerosil200, 
PEG6000 and PVP25 in the 10-wt% P/prefs were higher than those available in the 50-wt% P/prefs, which 
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indicate that different factors can affect the extent of drug release from the vehicles and hence its penetration 
rate into the mono-membrane, and these factors might overlap reversibly.   
The incorporation of the prefs in Dimethicone200 10-wt% ointment-SR has obtained similar results 
as those achieved with WHES.  
WHES contains as a lipoid component, 10-wt% fluid wax. Dimethicone200 10-wt% ointment-base 
was prepared from WHES, 10-wt% Dimethicone200 and 30-wt% water. As result to the addition of fluid 
wax200 the amount of lipoid in the DS-10-wt% ointment was slightly increased from 10% to 15%, and that 
of glycerol and the emulsifying wax were reduced, which made the vehicle slightly more hydrophobic. 
Thus, the following factors may be interrelated.  
The differences in penetration profiles of P and mhydr were smaller than those obtained when 
WHES was used alone. A better penetration has again resulted, when 50-wt% P/PEG6000-copr and P/A-
adsorbent were incorporated in the DS10-wt%-vehicle. Generally, using DS-wt10% as a base showed no 
advantage over WHES. However, the high amount of lipid contained in DS-wt 10% could sooth eczema 
efficiently.  
WWAS is w/o-emulsion type ointment-base, which consists of 50% WAS-ointment and 50%wt 
water. Therefore, it is impossible with WWAS to obtain an increased drug penetration from enhanced drug 
dissolution, because water lie in the internal phase. As F3 was incorporated in WWAS, (Figure 3, Curve S-
22) the penetration rate of the drug has clearly decreased. A comparison of S-19 with S-17 showed an 
increased penetration rate of F2 into the membrane. This behavior explains that the higher penetration rate 
has not been obtained due to enhanced drug-water-solubility, rather due to other factors. Moreover, this 
comparison indicates also that the hydrophobic character of the observed model-vehicles is continuously 
in increase. Following this tendency it could be concluded that the penetration profiles of the P/prefs with 
improved dissolution behavior decreases with increased vehicle-lipophilicity. Moreover, the absolute 
amounts of prednisolone released from the vehicles and entered into the membrane has continuously 
decreased after 15 as well after 150 minutes, permitting the conclusion that w/o-emulsion type ointment-
bases are more suitable for P as a base       
To understand if any crystal changes has happened, during and after the incorporation of  P in the 
various topical vehicles, X-ray diffraction studies were made, based on 10-wt% of P (1.0g pure P and 10.0g 
P/prefs/100g vehicle).  
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The X-ray diffraction patterns of pure WHES indicated peaks at 2 = 21.5 and 24.16. Peaks at the 
range of 2 = 12.0- 17.0 counted as for P and mhyd were not registered.   The XRDPs of a newly prepared 
S-45 (10% P in WHES) indicated a rapid crystal change of P into mhyd (Figure 6/a not shown). There were 
peaks registered at 2 = 13.8, 14.5, 15.1, 15.5, and 16.2. The peaks at 2 = 14.5 and 15.5 confirm 
that the change in crystal form has occurred readily during the preparation of S-45, and their heights grow 
continuously during the observation time period (Fig 6-B, not shown). 38 hrs later there were only peaks 
present at 2 = 14.4 and 14.9, which indicates that the occurred crystal form change was most probably 
due to the relatively high amount of water available in the outer phase of WHES. Moreover, the positions 
of the peaks deviate slightly from those of pure P, suggesting that a complete change in the crystal form of 
P into mhyd has happened. Thus, from a biopharmaceutical viewpoint P-ointments based on WHES should 
be considered as mhyd-ointments.  
The XDRPs of (10-wt% P/ DS-10-wt% ointment-SR) taken immediately after preparation indicated 
a fast change of the crystal form of P into its mhyd.  
The XRDPs of pure WWAS showed that at the angle range of 2 = 12º - 18º no peaks were present that 
might disturb the presence of P or its mhyd. The peaks immediately registered after the incorporation of P 
in WWAS and those taken after 120 hrs showed no significant change in its crystal form. WWAS is a 
lipophilic vehicle-type, by which an intimate contact between water and P is not possible. However, it is 
possible that the lipophilic phase (Vaseline) included in the vehicle has hydrophilized the crystal surface of 
P-particles. Accordingly, it could be concluded that the transformation of P into mhyd prepared with various 
vehicles has occurred in different velocities. This fact may affect greatly the bioavailability of P.   
The evaluation of the X-ray-difractograms taken for ointments containing P/prefs was difficult to 
perform for many reasons. One time the crystal form of P has partially changed into mhyd readily during 
the preparation of the prefs, and on the other hand unchanged crystals of P were also available. Thus, the 
interpretation of these peaks should not be taken as reliable. The XRDPs of P/PEG6000-copr/WHES taken 
immediately after preparation showed insignificant peaks, which might indicate a minimized P-
crystallinity. After 90 minutes there were very weak peaks of P present and 70 hrs later no significant 
change in their positions or heights could be observed. Obviously P lies mostly in the vehicle as unchanged.  
As this result was compared with those of S-45, it became evident that the incorporation of P-
PEG6000-copr in WHES has inhibited to a greater extent the transformation of P-crystal form into mhyd, 
this result suggests that the use of P/PEG6000-copr in WHES has minimized the formation of mhyd. This 
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situation can be considered as an explanation for the improved drug penetration rates, released from 
vehicles containing 50-wt% P/prefs. 
The X-ray studies of ointments containing P/PVP25-copr, and/or P/A-200 incorporated in WHES 
could not be accurately evaluated, because the peaks were very small, which  might indicate a reduced P-
crystallinity and/or an amorphous state. This fact became clearly evident, as we have had compared; for 
example the XRDPs of S-45, (fig 6, curves-A, B, C, not shown here) with those of S-48 and S-49, (each 
contains 10% P as prefs, Figures not shown). XRDP of S-50 (10% P as 50-wt% PVP25-copr/WHES) is 
another example for the same behavior. The peaks taken 95 hrs after preparation indicated that the 
incorporation of the 50% prefs in WHES has probably reduced the crystallinity of P and hence might have 
inhibited its total change into mhyd. As justification for this interpretation, the peaks at 2  º; ; 
and  are similar to those of pure P. XRDPs of S-45 showed that at this time P lied in WHES only as 
mhyd. One can conclude that the penetration of the poorly water-soluble drug co-precipitated with PEG6000 
prepared in ratio 1:1 and incorporated in WHES was significantly increased compared to the untreated drug.   
ACKNOWLEDGEMENT  
The author is very much grateful to Prof. G. Zessin of the department of pharmaceutics/ institute of 
pharmacy and Prof. R. Pollandt from the department of physical chemistry/ institute of chemistry/ Martin 
Luther University/Halle, of Germany for their valuable theoretical and technical support. 
   
Table 1: Dissolution profiles of the prednisolone/pre-formulations, F1, F2, A1, A2, F3 and F4, in pure water 
at 37C, by rotation speed of 50 rpm, paddle DT600 USP, (n = 6 tests, ±SD = mean values)  
  
                                                              
CONCENTRATIONS, [g/ml] 
 
Time,  prednisolone  F1     SD          F2         SD           F3      SD            F4      SD           A1     SD         A2      SD 
(hrs) 
------------------------------------------------------------------------------------------------------------------------------------------------    
1         14.6± 3.6        28.6± 1.8            20.6± 3.3             20.8± 0.8          19.4± 4.5          16.7± 3.0         18.7± 4.6 
2         17.8± 5.8        29.4± 9.0            21.4± 1.1             21.9± 3.5          20.7± 4.9          18.8± 6.3         19.6± 1.1 
3         19.3± 4.2        31.3± 9.8            23.1± 2.5             22.8± 3.4          21.6± 8.8          19.5± 8.7         20.4± 2.5 
4         19.6± 3.5        30.8± 12.4          24.0± 2.3             23.5± 2.6          21.5± 1.5          19.9± 7.3         21.4± 5.4 
5         19.8± 4.1        30.4± 3.80          23.5± 2.5             22.8± 7.6          20.3± 2.4          19.4± 9.9         19.4± 3.9 
6         20.4± 3.3        29.8± 11.5          23.1± 4.6             20.6± 3.4          20.0± 1.3          19.4± 9.9         19.4± 3.9  
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Table 2. X-ray diffraction patterns of pure prednisolone, its mono-hydrate, and the physical mixtures with 
PEG 6000, (F1 and F2) 
     
 
Preparations     Peaks at 2 
 
Pure Prednisolone (P)  13.8º, 15.1º, 16.2º, 17.9º 
Pure Prednisolone-monohyd.  14.3º, 15.6º 
Pure PEG 6000     13.0º, 13.5º, 14.5º, 15.05º    
Physical mixture of 10-wt% P  
+ 90-wt PEG 6000   13.5º, 13.9º, 14.6º, 15.1º, 15.5º, 16.2º, 17.65º    
Co-precipitate F1   13.7º, 15.04º, 15.5º, 15.9º, 16.3º, 16.8º 
Physical mixture of 50-wt% P 
+ 50-wt% PEG 6000-  13.7º, 14.9º, 15.3º, 15.8º, 16.0º, 17.9º 
Co-precipitate F2   13.8º, 15.1º, 15.6º, 16.3º, 17.9º     
 
  Table 3. Qualitative composition of the ointment-bases used  
  
1. Aqueous emulsifying wool-wax ointment-SR/GER, (WHES) 
Emulsifying wool-wax 21.0g 
Light Silicone oil 200 10.0g 
Glycerol  5.0g 
Propyl-paraben  0.06g 
Methyl-paraben  0.14g 
Ethanol 96%v/v  1.80g 
Purified water ad  100.00g 
2. Wool wax alcohol ointment-base-SR, (WAS) 
Wool wax-alcohols                                                                                      6.0g 
Cetostearyl alcohol   0.5g         
White Vaseline   93.5g  
        
3. Aqueous wool wax alcohol ointment-base-SR, (WWAS) 
Wool wax-alcohols ointment-base (WAS)    50.0g 
Purified water    50.0g 
4. Dimethicone oil200 ointment-base 10wt%-SR (DS10%wt)            
Dimethicone oil200     10.0g 
Aqueous emulsifying wool wax ointment-base (WHES)     60.0g 
Bacteriostatic water                              30.0g 
EDITORIAL  
Gezira Journal Of Health Sciences 2008 vol.4(1)  
 
Gezira Journal Of Health Sciences 2008vol.4(1) 
 
 
Table 4. In-vitro penetration rates of the pre-formulations, F1, F2, A1, A2, F3, and F4, incorporated in 
aqueous emulsifying wool wax ointment-base-SR/Ger. (= WHES)  
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34.6±3.17    
36.0±4.50    
37.7±2.55    























Abbreviations: oint. = ointment. Nr. = Number. S = reference to ointment. Penetr. = penetrated. AUC = area under the curve. 








Table 5. In-vitro penetration rates of the prednisolone-pre-formulations, F1, F2, A1, A2, F3 and F4, 
incorporated in aqueous wool wax alcohol-ointment-base-SR/Ger. (= WWAS) 
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Figure 1: Dissolution profiles of the prednisolone/ pre-formulations, F1, F2, A1, A2, F3 and F4 in pure water 
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Figure 2: In-vitro penetration rates of the prednisolone/ pre-formulations, F1, F2, A1, A2, F3 and F4, released 
from aqueous emulsifying wool wax ointment-base-SR/Ger, (WHES). 
 
 
Figure 3: In-vitro penetration rates of the prednisolone/ pre-formulations, F1, F2, A1, A2,  
F3 and F4, released from aqueous wool wax alcohols ointment-base/SR-Ger, (WWAS). 
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